CN104379138B - 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合 - Google Patents

阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合 Download PDF

Info

Publication number
CN104379138B
CN104379138B CN201280068973.8A CN201280068973A CN104379138B CN 104379138 B CN104379138 B CN 104379138B CN 201280068973 A CN201280068973 A CN 201280068973A CN 104379138 B CN104379138 B CN 104379138B
Authority
CN
China
Prior art keywords
acamprosate
tablet
dose
antipsychotic
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280068973.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104379138A (zh
Inventor
姜威霖
佛柏瑞
方刘纪礼
周三郎
黃大伟
林政德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synchroneuron Inc
Original Assignee
Synchroneuron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synchroneuron Inc filed Critical Synchroneuron Inc
Publication of CN104379138A publication Critical patent/CN104379138A/zh
Application granted granted Critical
Publication of CN104379138B publication Critical patent/CN104379138B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280068973.8A 2011-12-02 2012-12-02 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合 Active CN104379138B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161566550P 2011-12-02 2011-12-02
US61/566,550 2011-12-02
US201261649137P 2012-05-18 2012-05-18
US61/649,137 2012-05-18
PCT/US2012/067507 WO2013082573A1 (en) 2011-12-02 2012-12-02 Acamprosate formulations, methods of using the same, and combinations comprising the same

Publications (2)

Publication Number Publication Date
CN104379138A CN104379138A (zh) 2015-02-25
CN104379138B true CN104379138B (zh) 2021-12-07

Family

ID=48536156

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280068973.8A Active CN104379138B (zh) 2011-12-02 2012-12-02 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合

Country Status (14)

Country Link
EP (1) EP2785337B1 (enExample)
JP (1) JP6407720B2 (enExample)
KR (1) KR102055859B1 (enExample)
CN (1) CN104379138B (enExample)
AU (1) AU2012345659B2 (enExample)
BR (1) BR112014013374B1 (enExample)
CA (1) CA2863265C (enExample)
HK (2) HK1207563A1 (enExample)
IL (1) IL232935B (enExample)
MX (1) MX375183B (enExample)
RU (1) RU2671399C2 (enExample)
SG (1) SG11201403785UA (enExample)
WO (1) WO2013082573A1 (enExample)
ZA (1) ZA201404826B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN105431144A (zh) 2013-06-05 2016-03-23 思康脑侒股份有限公司 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
WO2020206107A1 (en) * 2019-04-03 2020-10-08 Synchroneuron Inc. Formulations
US12260944B2 (en) * 2019-10-11 2025-03-25 Hoffmann-La-Roche Inc. Drug dosage determination devices and methods
IL304905A (en) * 2021-02-15 2023-10-01 Kymera Therapeutics Inc IRAK4 joints and their uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1291091A (zh) * 1998-02-23 2001-04-11 默克专利股份有限公司 包含吸收促进剂的可口服给药的即释和缓释盖仑制剂以及吸收促进剂的用途
CN1293573A (zh) * 1998-01-13 2001-05-02 同步神经元有限责任公司 迟发性运动障碍和其它运动疾病的治疗方法
CN1697649A (zh) * 2003-04-29 2005-11-16 罗姆两合公司 药物剂型及其制备方法
CN101987081A (zh) * 2010-07-16 2011-03-23 钟术光 一种控释制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2284814C1 (ru) * 2005-04-08 2006-10-10 Государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства здравоохранения Российской Федерации" Способ лечения оптического неврита при оптикохиазмальном арахноидите в стадии ремиссии
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
WO2008073282A2 (en) * 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
EP2540294B1 (en) * 2010-02-22 2016-08-03 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
CA2850468C (en) * 2010-09-28 2019-08-13 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1293573A (zh) * 1998-01-13 2001-05-02 同步神经元有限责任公司 迟发性运动障碍和其它运动疾病的治疗方法
CN1291091A (zh) * 1998-02-23 2001-04-11 默克专利股份有限公司 包含吸收促进剂的可口服给药的即释和缓释盖仑制剂以及吸收促进剂的用途
CN1697649A (zh) * 2003-04-29 2005-11-16 罗姆两合公司 药物剂型及其制备方法
CN101987081A (zh) * 2010-07-16 2011-03-23 钟术光 一种控释制剂

Also Published As

Publication number Publication date
ZA201404826B (en) 2016-07-27
JP2015500812A (ja) 2015-01-08
IL232935A0 (en) 2014-07-31
CA2863265C (en) 2020-04-14
RU2014126879A (ru) 2016-01-27
KR102055859B1 (ko) 2019-12-13
AU2012345659A1 (en) 2014-07-24
IL232935B (en) 2020-11-30
AU2012345659B2 (en) 2017-09-28
EP2785337A4 (en) 2015-04-22
BR112014013374A2 (pt) 2017-06-13
EP2785337A1 (en) 2014-10-08
BR112014013374B1 (pt) 2022-10-11
MX375183B (es) 2025-03-06
KR20140121394A (ko) 2014-10-15
WO2013082573A1 (en) 2013-06-06
SG11201403785UA (en) 2014-10-30
CN104379138A (zh) 2015-02-25
RU2671399C2 (ru) 2018-10-31
BR112014013374A8 (pt) 2021-08-31
JP6407720B2 (ja) 2018-10-17
HK1207563A1 (en) 2016-02-05
AU2012345659A8 (en) 2014-08-07
EP2785337B1 (en) 2021-01-20
MX2014006574A (es) 2015-02-10
HK1199841A1 (en) 2015-07-24
CA2863265A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
US10512621B2 (en) Methods of treating posttraumatic stress disorder with acamprosate salts
US20150250746A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
JP5421511B2 (ja) 胃に留まるガバペンチン投薬を使用する処置方法
CN104379138B (zh) 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合
US20200222372A1 (en) Use of gaboxadol in the treatment of narcolepsy
US20110104272A1 (en) Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
MXPA06003125A (es) Composiciones farmaceuticas de modafinilo de liberacion modificada.
KR102039344B1 (ko) 프레가발린 함유 경구용 서방성 삼중정제
TW200800155A (en) Gastric retentive gabapentin dosage forms and methods for using same
JP2018506590A (ja) トリパルス放出型賦活薬製剤
US20210154161A1 (en) Modified-release bucillamine compositions, kits, and methods for treating cystinuria, arthritis, gout, and related disorders
KR102039345B1 (ko) 프레가발린 함유 고팽윤성 서방성 삼중정제

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1207563

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment